Skip to content
Open access

Treatment Effects of Different Therapeutic Strategies and Development of a Prognostic Prediction Model for Early Gastric Cancer: A Population-Based and Multicenter Study

Oct 2026 · Cancers · Vol 18, pp. 3488 · 0 citations · 54 references

TL;DR

This is the first externally validated EGC CSS model integrating all four treatments and supports individualized prediction and treatment decisions.

Abstract

Background: Early gastric cancer (EGC) lacks a predictive tool integrating endoscopic therapy (ET), gastrectomy (G), and chemoradiotherapy (CRT) to support individualized risk stratification. This study compared cancer-specific survival (CSS) and overall survival (OS) across the four treatment strategies and developed and externally validated a CSS prediction model incorporating oncologic characteristics and treatment strategy (presented as a nomogram and online tool). Methods: In a U.S. cohort (2017–2021), 1766 patients with EGC were classified into four treatments groups (ET, ET + CRT, G, G + CRT); an independent multicenter cohort (n = 1333) provided external validation. Kaplan–Meier curves, log-rank tests, and Cox regression assessed unadjusted differences, with confounding balanced by stabilized inverse probability of treatment weighting (sIPTW). Predictors were selected by univariable Cox, LASSO, Boruta, and best-subset regression; performance was evaluated by C-index, calibration curves, and decision curve analysis. Results: After sIPTW adjustment, CSS did not differ significantly between ET and G (p = 0.856), whereas G was associated with better CSS than G + CRT (p < 0.05). In exploratory analyses of node-positive patients, G + CRT was associated with lower cancer-specific mortality than G alone (p < 0.05). The CSS prediction model was validated internally and externally (AUCs for 1-, 3-, and 5-year CSS: 0.769, 0.737, 0.717 internally; 0.943, 0.890, 0.872 externally). Conclusions: This is the first externally validated EGC CSS model integrating all four treatments. For eligible patients, ET was associated with survival comparable to G and superior to G + CRT; among node-positive patients, G + CRT was associated with lower mortality than G alone. The model supports individualized prediction and treatment decisions.

Read PDF

Similar papers

Open access Oct 2026

Development and validation of a nomogram for predicting 5-year progression-free survival probability in differentiated thyroid cancer patients with lung metastases

Background and objective Progressive disease (PD) in differentiated thyroid cancer patients with lung metastases (DTC-LM) poses a significant clinical challenge, yet reliable predictive tools remain limited. This study aimed to develop and validate a nomogram for individualized prediction of 5-year progression-free sur...

Cong-Cong Wang, Xiao-Nian Zhang, Ying-Ying Zhang et al. · 0 citations
Open access Oct 2026

A cohort study on efficacy and safety of treatment modalities for resectable hepatocellular carcinoma with extrahepatic metastasis

Hepatectomy might provide a survival benefit over interventional and systemic therapy in carefully selected patients with resectable HCC and extrahepatic metastasis, particularly those with lung-only metastasis, preserved liver function, and no PVTT.

Tai-Xin Yang, Zhan Lu, Jie Zhang et al. · 0 citations
Oct 2026

Comparable cancer-specific survival but diminished adjuvant chemotherapy benefit in early-onset gastric cancer: A propensity score-matched analysis of SEER and Chinese cohorts.

BACKGROUND The incidence of early-onset gastric cancer (EOGC) is rising globally, whether its distinct clinicopathological profile translates into differential prognosis or chemotherapy efficacy remains contentious. METHODS We analyzed patients with stage Ⅰ-Ⅲ gastric adenocarcinoma undergoing curative gastrectomy fro...

Si-Han Zhang, Xin-Lin Wang, Li-Wen Ren et al. · 0 citations
Open access Sep 2026

Development and internal validation of a prognostic nomogram for cancer-specific survival in Ewing sarcoma: a SEER-based study

Background Ewing sarcoma is a rare and aggressive malignancy with substantial survival heterogeneity. Conventional tumor-node-metastasis (TNM) staging provides limited individualized prognostic assessment, and previous Surveillance, Epidemiology, and End Results (SEER)-based nomograms have rarely reported optimism-corr...

Shi-Long Wang, Long Jia · 0 citations
Open access Oct 2026

Prognostic Factors for Progression-Free Survival in Patients with Advanced Gastric Cancer Treated with First-Line Nivolumab Plus Oxaliplatin-Based Chemotherapy: Combined Clinical and Baseline CT Features

Background: Although nivolumab plus platinum-based chemotherapy has been approved as a first-line systemic treatment for advanced gastric cancer (AGC), the pretreatment imaging and clinical factors associated with disease progression remain incompletely understood. Methods: This retrospective study included 172 patient...

H. Rhee, Joon Seok Lim, Jin-Young Choi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.